This is an open-label, single-center, single dose, non-randomized, sequential, fixed-sequence
study, which will evaluate pharmacokinetics (PK) of dolutegravir (DTG) in healthy adult
subjects. The study will contain 6 periods with five prototype liquid formulations for
evaluation in fasted state. In period 1, 2 and 3 single reference dose of 2 dispersible
tablets of 5 milligram DTG will be administered and at least 2 liquid prototype DTG
formulations (containing a target total dose of 10mg DTG). There will be a wash-out period of
7 days between each period. In period 4 through 6, there would be options to evaluate
additional prototype liquid formulations. The total duration of study will be up to 17 weeks.
DTG has been found to be safe and effective in adults infected with human immunodeficiency
virus (HIV). DTG dispersible tablets have been developed primarily for use in children from 4
weeks to 6 years of age, and a DTG liquid formulation are is being developed to study the
appropriate dose needed for the HIV-exposed and infected neonatal population in the first
four weeks of life. Approximately 18 subjects will be enrolled in this study.